J1427
Skip to main content
Go to top
New York State Assembly
Speaker Carl E. Heastie
- Assembly Members
- Legislative Info
- Public Hearings
- Speaker's Press
- Assembly Reports
- Committees & More
- Bill Search Home
- Laws
- Legislative Calendar
- Public Hearing Schedule
- Assembly Calendars
- Assembly Committee Agenda
- Summary
- Actions
- Committee Votes
- Floor Votes
- Memo
- Text
- LFIN
- Chamber Video/Transcript
J01427 Summary:
| BILL NO | J01427 |
| SAME AS | No Same As |
| SPONSOR | PARKER |
| COSPNSR | |
| MLTSPNSR | |
J01427 Text:
Senate Resolution No. 1427 BY: Senator PARKER RECOGNIZING June 2026, as Scleroderma Awareness Month in the State of New York WHEREAS, It is the sense of this Legislative Body to recognize the importance of health awareness campaigns that educate the public, advance understanding of disease, support affected individuals and families, and foster research for improved diagnosis, treatment, and, ultimately, cures; and WHEREAS, Attendant to such concern, and in full accord with its long-standing traditions, this Legislative Body is justly proud to recognize June 2026, as Scleroderma Awareness Month in the State of New York; and WHEREAS, June is designated as Scleroderma Awareness Month, a time when advocates, healthcare providers, researchers, patients, caregivers, and communities across the Nation unite to elevate awareness about scleroderma, a rare autoimmune condition characterized by abnormal connective tissue growth that can affect the skin, blood vessels, and internal organs; and WHEREAS, Scleroderma encompasses a group of related disorders, including localized forms that affect mainly the skin and systemic sclerosis that can affect internal organs, each involving immune system dysfunction, fibrosis, vascular abnormalities, and serious complications such as pulmonary hypertension and interstitial lung disease; and WHEREAS, Scleroderma's clinical presentation is varied, and its diagnosis can be challenging because symptoms overlap with other conditions; there is currently no known cure for scleroderma, and management focuses on symptom control, organ protection, and supportive care; and WHEREAS, In the United States, more than 300,000 people live with a form of scleroderma, and the disease can affect individuals of all ages, genders, and backgrounds; awareness and early intervention are critical to improving quality of life and clinical outcomes for those affected; and WHEREAS, Research indicates that scleroderma disproportionately affects Black individuals in ways that result in more severe disease symptoms and poorer outcomes, including earlier age of onset, a higher frequency of the diffuse cutaneous form of systemic sclerosis, increased risk of organ involvement, and higher mortality rates when compared to white populations; this discrepancy warrants continued research, outreach, and culturally competent care; and WHEREAS, Awareness efforts during Scleroderma Awareness Month include national and local campaigns, educational programming, support group activities, community events, support services for patients and families, and opportunities for public acknowledgment such as proclamations, teal awareness lighting initiatives, and community dialogues; and WHEREAS, The National Scleroderma Foundation serves as a leading force in raising awareness, providing education and support to individuals and families, advocating for improved care, and fostering a nationwide network of support groups, including a Black, Indigenous, and People of Color (BIPOC) scleroderma support group to address community-specific needs and experiences; and WHEREAS, The Scleroderma Research Foundation is a national nonprofit organization dedicated to funding and advancing high-quality scientific research on scleroderma with the goal of discovering better treatments and ultimately a cure, supporting clinical study initiatives and collaboration among top researchers and institutions; and WHEREAS, During Scleroderma Awareness Month, communities are encouraged to learn more about this rare autoimmune disease, to support individuals living with scleroderma, to participate in awareness and fundraising activities, and to promote equitable access to clinical care, education, and research opportunities for all, particularly populations that have experienced disproportionate disease burden; now, therefore, be it RESOLVED, That this Legislative Body recognizes June 2026, as Scleroderma Awareness Month in the State of New York and reaffirms its commitment to raising public awareness about scleroderma, supporting affected individuals and families, advancing research and education, and addressing health disparities that affect Black and Brown communities; and be it further RESOLVED, That copies of this Resolution, suitably engrossed, be transmitted to the National Scleroderma Foundation and the Scleroderma Research Foundation in recognition of their leadership and service in support of the scleroderma community. Go to top <link href="/styles/noscript_styles.css" rel="stylesheet"/> Sitemap Request Information Directions and MapsOfficial text from the New York Legislature. Formatting has been adapted for reading on Ratifi.